

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 81876

**Title:** Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03353618

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** Slovenia

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2022-11-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-28 09:24

**Reviewer performed review:** 2022-12-04 11:06

**Review time:** 6 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

**statements**Conflicts-of-Interest: [ ] Yes [ **Y** ] No**SPECIFIC COMMENTS TO AUTHORS**

Authors in their paper presented the role of insulin resistance (IR) in CKD patients, also in association with cardiovascular diseases, which are the leading cause of morbidity and mortality of these patients. The paper is well written and interesting, potential mechanisms of IR in CKD patients are presented. They also present association of antidiabetic agents and IR. In this part, the role of antidiabetic drugs on IR in non-CKD patients is well described. The studies (if any) showing the role of antidiabetic drugs on IR in CKD patients (animals) should be discussed. If there is no study for a specific drug, that also has to be mentioned

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 81876

**Title:** Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05249683

**Position:** Editorial Board

**Academic degree:** BSc, MSc, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2022-11-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-05 17:09

**Reviewer performed review:** 2022-12-13 10:29

**Review time:** 7 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The contents of the manuscript covered the title and the manuscript abstract. The authors have to improve their manuscript by the following requirements: 1) insertion of designed figures for metabolic acidosis and vitamin D deficiency. 2) Change of the abbreviation of IR for insulin resistance. This abbreviation could be used for both insulin receptor and insulin resistance. It means insulin receptor in the manuscript in page 8 in the following sentence: A 2019 meta-analysis showed that DPP-4 inhibitors can improve both beta cell function and IR, although the effect was weak[66]. 3) The abbreviation of sodium-glucose co-transporter-2 inhibitors as SGLT2is is confusing. I recommend it to be SGLT2I. 4) A complete proofreading of the manuscript should be done to improve it. Please find a partially revised version with some corrected words (yellow-labeled).

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 81876

**Title:** Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06080454

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Saudi Arabia

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2022-11-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-05 12:02

**Reviewer performed review:** 2022-12-13 19:52

**Review time:** 8 Days and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The manuscript by Lin WR et al discuss the mechanism induction of insulin resistance in type 2 diabetes patient and how the diabetic nephropathy and CKD are developed. They also discussed the role of antidiabetic drugs and drugs for CKD in amelioration of insulin resistance in CKD patients. The review is fine. I have the following comments:-

- I suggest the title to be " Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease: A mini review - the abstract is short. Please increase the abstract to about 200 words. e.g. discuss the difference of the types of diabetes and the underlying mechanism initiate the insulin resistance. in addition to how the CKD is developed in T2D. - the author should cite the information in the text every 2 or 3 lines maximum. In the text, for example after a complete paragraph of the introduction there is only one reference. this should be revised. - the title should make a subtitle of conclusion and future perspective rather than only conclusion alone. -the authors should discuss these papers 1- Mir R. et al 2021, Molecular Determination of mirRNA-126 rs4636297, Phosphoinositide-3-Kinase Regulatory Subunit 1-Gene Variability rs7713645, rs706713 (Tyr73Tyr), rs3730089 (Met326Ile) and Their Association with Susceptibility to T2D. J Pers Med. 2021 Aug 29;11(9):861. doi: 10.3390/jpm11090861. 2- Michael P Czech 2017, Insulin action and resistance in obesity and type 2 diabetes, Nat Med, 11;23(7):804-814. doi: 10.1038/nm.4350.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 81876

**Title:** Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05249683

**Position:** Editorial Board

**Academic degree:** BSc, MSc, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2022-11-27

**Reviewer chosen by:** Jing-Jie Wang

**Reviewer accepted review:** 2023-02-16 08:55

**Reviewer performed review:** 2023-02-16 09:16

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Figures 1 & 2 are not downloaded in the manuscript file, but they are seen in both Answering-Reviewers-revision and image files. No more comments.